Leonardo Nicacio
About
Leonardo Nicacio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Leonardo Nicacio has authored 31 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Leonardo Nicacio's work include HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Prostate Cancer Treatment and Research (7 papers). Leonardo Nicacio is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Prostate Cancer Treatment and Research (7 papers). Leonardo Nicacio collaborates with scholars based in United States, Italy and Belgium. Leonardo Nicacio's co-authors include Anthony Brade, Gwyn Bebb, Colum J Smith, Ibrahima Soumaoro, Alexander Liede, Rohini K. Hernandez, Guru Sonpavde, Ian D. Schnadig, Menaka Bhor and Liji Shen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Leonardo Nicacio
29 papers receiving 282 citations
Peers
Leonardo Nicacio
Zhongmin Maxwell Wang Australia
Apurvasena Parikh United States
S. Stein United States
Joanna Pikiel Poland
Napapat Amornwichet Thailand
Matteo Repetto Italy
Fernando Cotait Maluf Brazil
Oyeon Cho South Korea
Craig Vargo United States
Hytham Al‐Masri United States
Citations per year, relative to Leonardo Nicacio Leonardo Nicacio (= 1×)
peers
Zhongmin Maxwell Wang
Countries citing papers authored by Leonardo Nicacio
Since
Specialization
Citations
This map shows the geographic impact of Leonardo Nicacio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonardo Nicacio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonardo Nicacio more than expected).
Fields of papers citing papers by Leonardo Nicacio
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leonardo Nicacio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonardo Nicacio. The network helps show where Leonardo Nicacio may publish in the future.
Co-authorship network of co-authors of Leonardo Nicacio
This figure shows the co-authorship network connecting the top 25 collaborators of Leonardo Nicacio. A scholar is included among the top collaborators of Leonardo Nicacio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonardo Nicacio. Leonardo Nicacio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kaklamani, Virginia, Joyce O’Shaughnessy, Peter Schmid, et al.. (2025). ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.. Journal of Clinical Oncology. 43(16_suppl).
2.
Sun, Lova, Jérôme Fayette, Sébastien Salas, et al.. (2024). Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.. Journal of Clinical Oncology. 42(16_suppl). 6012–6012.
3.
Passey, Chaitali, Jenna L. Voellinger, Leonid Gibiansky, et al.. (2023). Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1262–1273.
4.
Seiwert, Tanguy Y., Lara Dunn, Lova Sun, et al.. (2023). 681 innovaTV 207 Parts E and F: a phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress). SHILAP Revista de lepidopterología. A772–A773.
5.
Yonemori, Kan, Yasutoshi Kuboki, Kosei Hasegawa, et al.. (2022). Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer Science. 113(8). 2788–2797.
6.
Vergote, Ignace, Bradley J. Monk, Anneke M. Westermann, et al.. (2021). 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study. Annals of Oncology. 32. S726–S727.
7.
Hong, David S., Jérôme Fayette, Ariel E. Birnbaum, et al.. (2021). 930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors. Annals of Oncology. 32. S816–S816.
8.
Monk, Bradley J., Sonia Pulgar, Marley Boyd, et al.. (2021). Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. Gynecologic Oncology. 161(2). 422–428.
9.
Monk, Bradley J., Sonia Pulgar, Marley Boyd, et al.. (2021). Patient characteristics, treatment patterns and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: a community oncology-based real-world analysis. Gynecologic Oncology. 162. S227–S228.
10.
Coleman, Robert L., Domenica Lorusso, Christine Gennigens, et al.. (2020). LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. Annals of Oncology. 31. S1162–S1163.
11.
Blank, Stephanie V., Haider Mahdi, Sharad Ghamande, et al.. (2020). 882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer. Annals of Oncology. 31. S646–S646.
12.
Liede, Alexander, et al.. (2015). Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction. Clinical Epidemiology. 7. 441–441.
13.
Sonpavde, Guru, Menaka Bhor, Debajyoti Bhowmik, et al.. (2015). Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clinical Genitourinary Cancer. 13(4). 309–318.
14.
Houts, Arthur C., Mark S. Walker, Leonardo Nicacio, et al.. (2014). Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel. The Journal of Community and Supportive Oncology. 12(9). 321–328.
15.
Antonarakis, Emmanuel S., Paraskevi Giannakakou, Brian J. Kirby, et al.. (2013). TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 31(15_suppl). TPS5100–TPS5100.
16.
Schnadig, Ian D., Menaka Bhor, Nicholas J. Vogelzang, et al.. (2013). Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 31(6_suppl). 79–79.
17.
Schnadig, Ian D., Menaka Bhor, Nicholas J. Vogelzang, et al.. (2013). Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). 4.
18.
Nicacio, Leonardo, et al.. (2011). Castrate-resistant prostate cancer: clinical as well as economic factors should influence treatment practice. 2.
19.
Bebb, Gwyn, et al.. (2010). Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemotherapy and Pharmacology. 67(4). 837–845.
20.
You, Benoît, Anthony Brade, Lillian L. Siu, et al.. (2010). A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Investigational New Drugs. 29(5). 996–1003.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Apurvasena Parikh Breakdown of academic impact, for papers by S. Stein Breakdown of academic impact, for papers by Joanna Pikiel Breakdown of academic impact, for papers by Napapat Amornwichet Breakdown of academic impact, for papers by Matteo Repetto Breakdown of academic impact, for papers by Fernando Cotait Maluf Breakdown of academic impact, for papers by Oyeon Cho Breakdown of academic impact, for papers by Craig Vargo Breakdown of academic impact, for papers by Hytham Al‐Masri